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Abstract: A glycinate derivative of α-methylprednisolone (MP) was prepared and conjugated 
to a linear cyclodextrin polymer (CDP) with a loading of 12.4% w/w. The polymer conjugate 
(CDP-MP) self-assembled into nanoparticles with a size of 27 nm. Release kinetics of MP 
from the polymer conjugate showed a half-life (t1/2) of 50 h in phosphate buffer solution (PBS) 
and 19 h in human plasma. In vitro, the proliferation of human lymphocytes was suppressed 
to a similar extent but with a delayed effect when CDP-MP was compared with free MP. In 
vivo, CDP-MP was administered intravenously to mice with collagen-induced arthritis and 
compared with free MP. CDP-MP was administered weekly for six weeks (0.07, 0.7, and 
7 mg/kg/week) and MP was administered daily for six weeks (0.01, 0.1, and 1 mg/kg/day). 
Body weight changes were minimal in all animals. After 28 days, a signiﬁ  cant decrease in 
arthritis score was observed in animals treated weekly with an intermediate or high dose of 
CDP-MP. Additionally, dorsoplantar swelling was reduced to baseline in animals treated with 
CDP-MP at the intermediate and high dose level. Histological evaluation showed a reduction in 
synovitis, pannus formation and disruption of architecture at the highest dose level of CDP-MP. 
MP administered daily at equivalent cumulative doses showed minimal efﬁ  cacy in this model. 
This study demonstrates that conjugation of MP to a cyclodextrin-polymer may improve its 
efﬁ  cacy, leading to lower doses and less frequent administration for a safer and more convenient 
management of rheumatoid arthritis.
Keywords: α-methylprednisolone (MP), cyclodextrin polymer (CDP), polymer conjugate 
(CDP-MP), rheumatoid arthritis (RA), enhanced permeability and retention effect (EPR)
Introduction
Rheumatoid arthritis (RA) is a chronic disease that causes inﬂ  ammation on the 
synovial membrane that protects and lubricates the joints (Bodman and Roitt 1994). 
In advanced stages of disease, it can cause deformity and loss of joint function with 
severe pain. More than two million Americans are affected by RA (Lawrence et al 
1998). There is no known cure for this disease. RA patients are treated with three 
general classes of drugs such as disease-modifying antirheumatic drugs (DMARDs), 
nonsteroidal anti-inﬂ  ammatory agents (NSAIDs), and corticosteroids to reduce joint 
inﬂ  ammation and pain, maximize joint function, and prevent joint destruction and 
deformity (Byron and Mowat 1985; Hyrich et al 2006). Methylprednisolone (MP), 
a corticosteroid (GC), was chosen as a candidate for our study. In the classic mode 
of action, GCs diffuse into the cytoplasm and bind to the ubiquitous glucocorticoid 
receptor (cGCR). The cGCR is a multiprotein complex that sheds HSP90 and other 
chaperones after GC binding, followed by nuclear translocation of the complex. In 
the nucleus, the activated cGCR leads to induction or inhibition of transcription of 
speciﬁ  c regulator proteins. In addition to these genomic effects, rapid nongenomic International Journal of Nanomedicine 2008:3(3) 360
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actions also occur. Nongenomic effects are less well deﬁ  ned 
but are proposed to involve membrane-bound glucocorticoid 
receptors, nonnuclear cytosolic effects, and effects medi-
ated through nonspeciﬁ  c membrane binding of GC at high 
doses (Farrell and Kelleher 2003; Buttgereit et al 2004). 
Downstream effects of GCs include the following: Inhibition 
of inﬂ  ammatory mediators (IL-1, TNF-α, GM-CSF, IL-3, 
IL-4, IL-5, IL-8, prostaglandins, nitric oxide), inhibition of 
lymphocyte proliferation, inhibition of inﬂ  ammatory cell 
migration, and induction of apoptosis in thymocytes.
MP is a synthetic glucocorticoid drug taken orally or 
administered intravenously. MP is commonly used in arthritis 
therapy and other acute and chronic inﬂ  ammatory diseases 
(Hayball et al 1992; Okada 2005). Short term i.v. pulses of 
MP are useful as bridge therapy in patients refractory to other 
therapies (Laan et al 1999) and play a role in combination 
therapy with newer biological DMARDs with slow onset of 
activity (Konttinen et al 2005). Intravenous doses of meth-
ylprednisolone, however, have high rate of clearance. Due 
to inadequate distribution of MP to site of inﬂ  ammation, it 
requires large and frequent dosing (7.5 mg/day when given 
on a daily oral schedule, up to 1000 mg every other day when 
given intravenously) to achieve an appropriate therapeutic 
effect (Snell 1976; Laan et al 1999). Although MP is known 
to be very effective in inﬂ  ammatory diseases, it has serious 
side effects upon chronic exposure, including weight gain, 
glaucoma, osteoporosis, and psychosis (Saag 2002). One 
approach to reduce dosing amounts, frequency of adminis-
tration, and adverse side effects while maintaining the drug 
efﬁ  ciency, is the development of new drug delivery systems 
with inﬂ  ammatory site targeting and long circulating time.
Liposomes or polymer conjugates for inflammatory 
diseases are currently under active study by many research 
groups (Chandrasekar et al 2007; Khoury et al 2006). Poly-
mer conjugates or liposomes are able to stabilize drugs and 
prolong their plasma half-life. Polymer conjugates are dif-
ferent from liposome systems in that drugs are bound to the 
carrier instead of being trapped in the cavity of the particles. 
Polymer conjugates of drugs have gained interest for phar-
maceutical applications over the last two decades for their 
excellent ability to reduce toxicities while maintaining or 
increasing efﬁ  cacy (Duncan 2003; Vicent 2007). Polymer 
conjugates can extend release pharmacokinetics and result in 
improved biodistribution characteristics through the so-called 
enhanced permeability and retention (EPR) effect (Matsumura 
and Maeda 1986). The EPR effect has been characterized as 
the ability of long-circulating macromolecules to extravagate 
through the abnormally leaky vasculature in tissues with 
deregulated neovascularization and inadequate lymphatic 
drainage, such as tumors, leading to drug accumulation.
The linear cyclodextrin polymer (CDP) is composed of 
β-cyclodextrin and poly ethylene glycol (Figure 1). CDP 
is water-soluble, biocompatible, nontoxic, and nonimmu-
nogenic (Cheng et al 2003; Schluep et al 2006a, 2006b). 
CDP conjugates of hydrophobic small molecule drugs 
self-assemble into nanoparticles with diameters between 
30–50 nm. Preclinically, nanoparticulate CDP conjugates 
have been shown to accumulate in tumor tissue through the 
EPR effect (Schluep et al 2006b). Rheumatoid arthritis is also 
known to cause deregulated formation of new blood vessels 
in the inﬂ  amed joints. Liposomes and polymer conjugates 
have been shown to accumulate at the sites of inﬂ  ammation 
due to locally enhanced capillary permeability (Paleolog and 
Fava 1998). In fact radioactively labeled liposomes with a 
sub-100-nm size have been used successfully to image and 
detect sites of inﬂ  ammation in both animal models of arthritis 
as well as in humans (Boerman et al 1997; Dams et al 1999; 
Laverman et al 1999).
Here, we investigate a nanoparticulate CDP conjugate of 
MP, in which the drug is conjugated to the polymer through 
a glycinate ester (Figure 1). An ester linker was used because 
most ester prodrugs show acceptable stability in vitro while 
allowing suitable drug release in vivo (Mørk and Bundgaard 
1992; Sriram et al 2004). Ester prodrugs can be activated by 
pH-dependent hydrolysis and enzyme-induced cleavage. 
Elevated esterase levels have been detected in the synovial 
ﬂ  uid of rheumatoid arthritic patients providing a mechanism 
for site-speciﬁ  c release of ester-linked prodrugs (Kar et al 
1976). CDP-MP nanoparticles were studied in vitro for their 
ability to inhibit the proliferation of human lymphocytes and 
in vivo in order to determine their efﬁ  cacy in a collagen-
induced arthritis model after intravenous delivery.
Materials and methods
General
Unless otherwise speciﬁ  ed, chemicals were purchased from 
Aldrich (St. Louis, MO) and used without further puriﬁ  cation. 
Cyclodextrin polymer (CDP) was prepared according to the 
previous procedure (Cheng et al 2003). α-methylprednisolone 
was purchased from Steraloids, Inc (Newport, RI). Lyophi-
lized human plasma was purchased from Sigma (St. Louis, 
MO) and reconstituted with PBS. NMR spectra were recorded 
on a Varian AMX 500 MHz or a Varian 300 MHz spec-
trometer. Mass spectral (MS) analysis was performed using 
either an electrospray mass spectrometer equipped with LCQ 
ion trap (Thermo Finnigan, Waltham, MA) and ﬁ  tted with International Journal of Nanomedicine 2008:3(3) 361
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an electrospray ionization source or a MALDI-TOF mass 
spectrometer (Voyager DE-PRO, Applied Biosystems, Fos-
ter City, CA). MWs of the polymer samples were analyzed 
on a GPC system equipped with Agilent 1100 Series HPLC 
system, a Wyatt DAWN Heleos, Wyatt Optical rex, and two 
gel permeation columns in series (PL-aquagel-OH-40 8 μm 
300 × 7.5 mm and PL-aquagel-OH-50 8 μm 300 × 7.5 mm, 
Polymer Laboratories, Amherst, MA) calibrated using 
poly(ethyleneoxide) standard and eluted using PBS (1X) at 
a concentration of 6 mg/mL and at a 1.0 mL/min ﬂ  ow rate at 
30 °C. Release kinetics and polymer drug-loading of the MP 
derivative were analyzed with a C-18 reverse phase column 
on a Agilent 1100 HPLC system equipped with an UV detec-
tor at 250 nm using an isocratic mobile phase of potassium 
phosphate buffer (pH 4.1) and acetonitrile. Particle size of 
CDP-MP was measured on Zeta PALS, Brookhaven Instru-
ment Corporation (Holtsville, NY).
Synthesis of 21-O-t-Boc-glycinate ester 
of α-methylprednisolone (MP) 
and 21-O-triﬂ  uo glycinate ester of MP
t-Boc-glycine (0.42 g, 2.4 mmol) was dissolved in 50 mL 
of anhydrous tetrahydrofuran at room temperature, and 
to this solution were added N,N’-Diisopropylcarbodi-
imide (0.30 g, 2.4 mmol), 4-(Dimethylamino)pyridine 
(33 mg, 0.27 mmol), and MP (1.0 g, 2.77 mmol) at 0 °C. 
The reaction mixture was stirred for ½ h at 0 °C and then 
stirred at room temperature for additional 15 h. Tetrahy-
drofuran was removed under reduced pressure to yield 
a white solid. The solid was redissolved in diethyl ether 
(50 mL) and washed with 0.1N HCl (10 mL) twice. It 
was then dried over MgSO4 and reduced under vacuum 
to yield white solid. It was purified by flash column 
chromatography using methylenechloride:acetone (9:1) 
mixture to yield white solid (0.88 g, 62%). 1H NMR 
(CDCl3) δ 7.31 (d), 6.26 (q), 6.00 (s), 5.02 (m), 4.47 
(m), 4.04 (m), 2.98 (s), 2.68 (m), 2.22 (m), 2.11 (m), 
1.82–1.60 (m), 1.40 (m), 1.10 (m), 1.03 (m), 0.94 (s). ESI/
MS (m/z) expected 531.28; Found 554.1 (M + Na).
21-O-t-Boc-glycinate ester of α-methylprednisolone (110 mg, 
0.21 mmol) was dissolved in a mixture of methylenechloride (10 
mL) and triﬂ  uoroacetic acid (TFA) (10 mL) and stirred at room 
temperature for 1 h. TFA glycinate MP was precipitated in diethyl 
ether (100 mL), washed with diethyl ether (20 mL) twice and 
the solids were dried under vacuum to yield white solid (38 mg, 
34% Yield). 1H NMR (D2O) δ 7.36 (d), 6.17 (q), 5.88 (s), 5.04 
(m), 4.28 (m), 3.93 (s), 2.56–2.00 (m), 1.97–1.75 (m), 1.58 (m), 
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Figure 1 Schematic representation of the structure of CDP-MP,  a conjugate of a glycinate derivative of α-methylprednisolone (MP) and a cyclodextrin polymer (CDP). m Number 
of ethylene glycol repeating units (average m = 77 for PEG with Mw 3,400); n number of repeating units of CDP-MP (average n = 24 ± 5 for parent polymer Mw of 117 kDa).International Journal of Nanomedicine 2008:3(3) 362
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1.48–1.27 (m), 1.23 (s), 0.94 (m), 0.82 (m), 0.67 (s). ESI/MS 
(m/z) expected 431.23; Found 431.9 [M]+.
Synthesis of CDP-MP
CDP (1.0 g, 0.21 mmol) was dissolved in dry N,N-dimeth-
ylformamide (20 mL). The mixture was stirred for 20 min. 
21-O-triﬂ  uoro glycinate ester of MP (250 mg, 0.46 mmol), 
N,N-diisopropylethylamine (0.080 mL, 0.46 mmol), N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 
(120 mg, 0.62 mmol), and N-hydroxysuccinimide (52 mg, 
0.46 mmol) were added to the polymer solution and stirred 
for 4 h. The polymer was precipitated with ethylacetate (100 
mL). The precipitate was dissolved in pH3 water (100 mL) 
which was prepared by acidiﬁ  cation with HCl. The solution 
was dialyzed using 25,000 MWCO membrane (Spectra/
Por 7) for 24 h in pH3 water. It was ﬁ  ltered through 0.2 μm 
ﬁ  lters (Nalgene) and lyophilized to yield white solid (630 mg, 
50%). Loading of MP was determined to be total of 12.4% 
with 0.08% free MP by HPLC.
Release of MP from conjugates
Release of MP in PBS
CDP-MP was dissolved in PBS (1x, pH 7.4) at a concen-
tration of 1 mg/mL and incubated at 37 °C. Samples were 
quenched by addition of 8.5% H3PO4 at selected time point 
and stored at −80 °C until the analysis. The released MP was 
measured by HPLC at 250 nm and compared to a standard 
curve of MP.
Release of MP in human plasma
CDP-MP was dissolved in PBS (1x, pH 7.4) at a concentra-
tion of 1 mg/mL. Human plasma was prepared at a concen-
tration of 1 mg/mL. 250 μL of each solution, CDP-MP and 
human plasma was aliquoted and combined to make the total 
volume of 500 μL. Samples were then incubated at 37 °C, 
quenched at selected time point by addition of 8.5% H3PO4 
and stored at −80 °C until the analysis. It was then loaded 
on a preconditioned solid phase column (Oasis HLB 1 cm3 
cartridge from Waters, Milford, MA) and eluted with 5 mL 
with acetonitrile. Spike recovery was greater than 99%. 
The released MP was measured by HPLC at 250 nm and 
compared to a standard curve.
In vitro evaluation
Isolation and culture of leukocytes for analysis
Peripheral blood mononuclear cells (PBMC) were used 
as a source of lymphocytes/monocytes from a human 
source. Human PBMC were isolated from whole blood 
by Ficoll-Hypaque gradient centrifugation. The cells were 
cultured at 1 × 106 cells/ml (2 × 105 cells/well) in RPMI 
1640 supplemented with 25 mM HEPES, 4 mM l-glutamine, 
100 U/ml penicillin/streptomycin, and 10% heat inactivated 
FBS. The cells were exposed either to MP or CDP-MP prepa-
rations in the presence of phytohemagglutinin or concanavilin 
A (mitogens for T cells).
Lymphocyte proliferation (Mitogen)
For the evaluation of lymphocyte proliferation in response 
to mitogen, cultures were set up in microtiter plates. Cells 
were exposed either to MP or CDP-MP preparations 
(1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001, 0.0003, 0.0001, 
0.00003, 0.00001, and 0.000003 μg/mL) in the presence 
of phytohemagglutinin L (PHA, 10 μg/ml) or concanavilin 
A (Con A, 1.25 μg/mL) (mitogens for T cells). Controls 
included stimulated cultures and cultures with no stimulus. 
At 2 or 4 days after initiation of culture, tritiated thymi-
dine was added to the cultures to be incorporated in the 
DNA undergoing synthesis. Cells were cultivated without 
replenishing the media for the duration of the study. At 3 
or 5 days after initiation of culture, the cells were harvested 
via a multiwell harvester and the amount of thymidine 
incorporated (as a measure of proliferation) was assessed 
by scintillation counter.
Analysis
After counting of thymidine incorporation, the data were 
analyzed for stimulation index (the level of thymidine incor-
poration in stimulated cultures over thymidine incorporation 
in unstimulated cultures). Further the level of decrease in 
proliferation caused by MP or CDP-MP compared with 
untreated, stimulated cultures was assessed.
In vivo study in immune mediated
arthritis model
Animal care
All animals received humane care as deﬁ  ned by the National 
Research Council’s criteria for humane care. The study pro-
tocols were approved by the Institutional Animal Care and 
Use Committee before initiation of the studies.
Sample preparation
A stock of 5 mg/mL MP was made in absolute ethanol for 
the nonconjugated formulation. This stock was then diluted 
to 200 μg/ml (1 volume of stock + 24 volumes of saline) for 
the top dose. Ten fold dilutions were prepared in saline for the 
lower doses. CDP-MP was diluted in 5% aqueous dextrose International Journal of Nanomedicine 2008:3(3) 363
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solution (D5W). As control groups, methyl prednisolone 
diluent injection and CDP (polymer alone control) in D5W 
were compared with drug-dosed groups.
Arthritis induction and assessment
Arthritis was induced in mice by immunization with bovine 
collagen type II (CII) in adjuvant in the skin at the base of 
the tail, and assessed regularly (Cannetti et al 2003). Bovine 
CII was dissolved in 10 mM acetic acid at a concentration 
of 4 mg/mL. Emulsiﬁ  cation of antigen in Freund’s complete 
adjuvant (CFA; Sigma Aldrich) was carried out by passing 
between two locking hub syringes with the apparatus at 4 °C 
to ensure stability of the collagen. DBA/1 mice (Harlan, 
Livermore, CA) were injected with 100 μg of CII in CFA 
at the base of the tail on day zero. On day 21 mice received 
a booster injection of 50 μg of CII in incomplete FA (IFA; 
Sigma Aldrich) to improve the incidence and synchronization 
of arthritis onset. On day 29 animals were scored and divided 
equally into groups with equivalent severity of arthritis. They 
were then treated with MP, CDP-MP or placebo according to 
Table 1. Typically 80% of animals develop arthritis. Fifty 
animals were immunized and 40 were carried on for further 
treatment. Assessments were conducted by an independent 
operator. After the start of therapy, the mice were weighed 
twice weekly.
Arthritis score
Joint swelling was scored (arthritis score) by a standardized 
method by an experienced observer. In brief, a score of 0–4 
is assigned as follows: 0 – no evidence of hyperemia and/or 
inﬂ  ammation; 1 – hyperemia with little or no paw swelling; 
2 – swelling conﬁ  ned predominantly to the ankle region with 
modest hyperemia; 3 – increased paw swelling and hyper-
emia of the ankle and metatarsal regions; 4 – maximal paw 
swelling and hyperemia involving the ankle, metatarsal and 
tarsal regions. For ﬁ  nal analysis scores were summed for all 
paws, thus the maximum possible score was 16.
Dorsoplantar swelling
Paw thickness was measured with 0–10-mm calipers. Dorso-
plantar swelling was measured twice weekly after initiation 
of treatment until the onset of necropsy.
Histological evaluation
Animals were sacriﬁ  ced on day 42. Front and rear paw sec-
tions were removed and bisected following sacriﬁ  ce, and the 
paw was ﬁ  xed in 10% neutral buffered formalin for at least 
5 days before decalciﬁ  cation for 18 days in 10% formic acid. 
Paws were then dehydrated and embedded in parafﬁ  n blocks. 
Sections (5 μm thickness) were cut along a longitudinal axis, 
mounted, and stained with hematoxylin and eosin (H+E). 
Specimens were cut approximately to the mid line, and then 
sagittal central samples mounted for evaluation. The sec-
tions were stained with H+E, and Masson's trichrome stain 
(Wong et al 2006). Images at a 100x magniﬁ  cation were 
captured using a Nikon E600 microscope equipped with a 
digital camera. Histological analysis was determined by a 
blinded pathologist using a validated scoring system for cel-
lular inﬁ  ltrate, synovial hypertrophy, and bone destruction. 
Histological analysis was conducted to determine the extent 
of joint damage. A minimum of three separate sections per 
specimen were evaluated in a blinded fashion. On the front 
paws, wrist and metacarpal joints were scored and on the rear 
paws, ankle, and metatarsal joints were scored. Slides were 
evaluated for the presence of synovitis, pannus formation, 
marginal erosions, architectural changes (mostly sublux-
ation), and destruction. Synovitis was judged by thickness of 
the synovial membrane and scored from 1 (less than 3 cells 
thick) to 5 (beyond 30 cells thick); pannus was scored as 0 
(no erosions visible) to 5 (loss of visible cartilage and major 
Table 1 In vivo assay of CDP-MPa
Group No.    Animals Treatment  Dose  (mg/kg) Route Schedule
1 5  Control  n/a  iv  qdx42
2  5 Polymer  control  70 iv  qwkx6
3  5  MP (Low dose)  0.01  sc  qdx42
4  5  MP (Medium dose)  0.1  sc  qdx42
5  5  MP (High dose)  1  sc  qdx42
6  5  CDP-MP (Low dose)  0.07  iv  qwkx6
7  5  CDP-MP (Medium dose)  0.7  iv  qwkx6
8  5  CDP-MP (High dose)  7  iv  qwkx6
Notes: aOn day 29 after the initiation of immunity to CII, the animals began to receive therapy. The injections were given as described above until necropsy on day 42. The 
methyl prednisolone in diluent was injected subcutaneously and the conjugate containing preparations was injected intravenously. Injections were made in 100 μl volume. 
CDP-MP doses are in MP equivalents. Polymer control was CDP without any drug in D5W.
Abbreviations: MP, α-methylprednisolone; CDP-MP, polymer conjugate; IV, intravenous; sc, subcutaneous; qd, daily; qwk, weekly.International Journal of Nanomedicine 2008:3(3) 364
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bone loss due to erosion); architectural changes scored from 
0 (normal joint architecture) to 5 (complete ﬁ  brosis and col-
lagen bridging). An overall score based on these collective 
points ranging from 0 (classical normal joint appearance) 
to 5 (destructive erosive arthritis with major bone remodel-
ing), was then assigned to each section. The loss of bone 
and cartilage components was assessed. Masson's trichrome 
histological staining was used to quantify the bone collagen 
content as a parameter of bone osteolysis.
Statistical evaluation
Statistical signiﬁ  cance between the different treatment 
groups and untreated controls was evaluated using a 
Student’s two-sample, two-tailed t-Test with unequal vari-
ance (hetroscedastic) in Microsoft Excel (Microsoft Corp., 
Redmond, WA).
Results
Synthesis of CDP-MP
An MP glycinate derivative was prepared by attaching gly-
cine to the primary alcohol group of MP through an ester 
linkage. Glycinate MP was then covalently attached to CDP 
(MW 117 kDa). The conjugate was puriﬁ  ed by dialysis and 
lyophilized to yield a white solid. The amount of MP bound 
to CDP was determined to be 12.4% (w/w) with 0.08% of 
free MP by HPLC. CDP conjugation of MP changed the 
water solubility of MP from insoluble (0.12 mg/mL) to highly 
soluble (than 200 mg of CDP-MP/mL). The particle size 
of the polymer conjugate in deionized water was measured 
to be 27 nm by dynamic light scattering (DLS; Table 2). 
Particle size of the conjugate (10 mg/mL) was also evalu-
ated in physiological conditions (PBS, pH 7.4) at both 25 
and 37 ºC and found to be 26 and 30 nm, respectively (data 
not shown). The stability of nanoparticles was monitored by 
incubation of the CDP-MP conjugate (10 mg/mL) in PBS 
(pH 7.4) or water for up to 45 hours at 37 ºC. No signiﬁ  cant 
change in particle size was observed in either solvent over 
that time period (data not shown).
In vitro evaluation
Release of MP from conjugates
Release kinetics of MP from the conjugate were investigated 
in PBS (pH 7.4) and human plasma (pH 7.4) at 37 ºC over 
3 days (Figure 2). In PBS, the half-life (t1/2) of MP released 
from the polymer was 50h. In human plasma, the half-life 
(t1/2) of MP released from the polymer was 19 h. The half-life 
of MP in human plasma was expected to be shorter due to the 
presence of esterases (Mørk et al 1992; Sriram et al 2004).
Release of MP from the conjugates also resulted in the 
disassembly of the nanoparticles to single polymer strands. 
While CDP-MP conjugates had particle size of 27 nm by 
DLS, treatment of CDP-MP with base resulted in a com-
plete release of drug from the conjugate and a concomitant 
reduction in particle size to 9.7 nm, corresponding to the 
single strand hydrodynamic diameter of the parent polymer 
(Table 2).
Inhibition of proliferation of human 
lymphocytes
The effect of MP and CDP-MP on the proliferation of 
human lymphocytes was evaluated at day 3 and day 5 after 
initiation of culture (Table 3). Proliferation of human lym-
phocytes was induced by exposing them to concanavilin A 
(Con A) or phytohemagglutinin L (PHA), two potent mito-
gens. The stimulation of human cells with Con A and PHA 
did result in increased proliferation of the control cells. 
Concomitant incubation of stimulated cells with MP and 
CDP-MP lead to a concentration dependent inhibition of 
lymphocyte proliferation. A difference in the concentration 
of drug needed to cause a 50% reduction in cell prolifera-
tion (IC50 of the stimulation index) was observed between 
the different treatment groups. In the 3 day assay and for 
Con A as a stimulus, the IC50 of free MP was determined 
to be 0.0069 μg/mL where that of CDP-MP was four times 
higher at 0.025 μg/mL. For PHA as a stimulus, the 3 day 
IC50 of free MP was 0.029 μg/mL and the IC50 of CDP-MP 
was 0.67 μg/mL. The Con A stimulated cells were more 
sensitive to treatment with the steroid formulations than the 
PHA stimulated cells.
In the 5 day assay the Con A stimulated cells were also 
more sensitive to treatment with the steroid formulations 
than the PHA stimulated cells. For Con A as a stimulus, 
the IC50 of free MP was 0.00088 μg/mL whereas the IC50 
of CDP-MP was 0.000024 μg/mL. The conjugate was 36 
times more potent than free MP. For PHA as a stimulus, the 
IC50 of free MP was 0.021 μg/mL and the IC50 of CDP-MP 
Table 2 Comparison in particle size of CDP after MP loading and 
drug releasea (n = 5)
Polymer Particle  size  (nm)  Polydispersity
CDP 8.1  ± 0.2  0.282
CDP-MP 27  ± 0.3  0.224
CDP (after MP release)  9.7 ± 0.8  0.289
Notes: aFor particle sizing by dynamic light scattering (DLS), 10 mg of polymer was 
dissolved in 1.0 mL of nano-pure water at 25 ºC.
Abbreviations: CDP, cyclodextrin polymer; MP, α-methylprednisolone; CDP-MP, 
polymer conjugate.International Journal of Nanomedicine 2008:3(3) 365
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was 0.096 μg/mL. Free MP was approximately four times 
as potent as CDP-MP in that case.
In vivo evaluation
The effect of MP and CDP-MP on a murine model of collagen-
induced arthritis was evaluated for 42 days after 28 days of 
collagen induction time (Figure 3). Free MP was subcutane-
ously dosed at dosages of 0.01, 0.1, and 1.0 mg/kg/day for 
the period of the study while CDP-MP was intravenously 
dosed at dosages of 0.07, 0.7, and 7.0 mg/kg/week, resulting 
in equivalent cumulative weekly doses in the low, medium 
and high dose groups for both agents. There were sporadic 
changes in body weight over the course of the study in all the 
treatment groups, however these changes were not consistent 
over time (data not shown). The major changes seen in the 
study were in symptoms of arthritis. Arthritis score is a gross 
composite measure of swelling and the extent of arthritic 
changes observed. The animals were randomized at baseline 
to have approximately equivalent arthritic scores. As time 
went on, the scores became worse. Polymer control (CDP) 
and free MP at the two lower dose levels showed responses 
similar to placebo treated animals. The highest dose of free 
MP (1 mg/kg/day) and CDP-MP at 0.07 mg/kg/week showed 
a similar reduction in arthritis scores after day 28, however the 
effect was not statistically signiﬁ  cant (p  0.16). In contrast, 
a signiﬁ  cant reduction in arthritis score after day 28 was seen 
in groups of animals treated with the two highest doses of 
CDP-MP at 0.7 and 7.0 mg/kg/week (p  0.006).
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Figure 2 Release kinetics of MP from the conjugates in PBS (pH 7.4) and human plasma (pH 7.4) at 37 °C over 3 days.
Table 3 Calculated IC50 values for the stimulation index in human lymphocytes for MP and conjugated MP (μg/ml in MP equivalents)a 
(n = 3)
Stimulus  Time point  MP IC50
b 95%  Conﬁ  dence intervalb CDP-MP  IC50
b 95%  Conﬁ  dence intervalb
Con A  Day 3  0.0069  0.0045–0.010  0.025  0.010–0.061
PHA Day  3 0.029  0.015–0.054  0.67  0.15–3.1
Con A  Day 5  0.00088  0.00035–0.0020  0.000024  0.0000041–0.00014
PHA Day  5 0.021  0.010–0.043  0.096  0.051–0.18
Notes: aStimulation index = level of thymidine incorporation in stimulated cultures over thymidine incorporation in unstimulated cultures. bIC50 and 95% conﬁ  dence interval 
were determined by using the Graphpad Prism 4 software (Graphpad Inc., La Jollla, CA).   A sigmoidal dose-response curve was ﬁ  tted to the data (Y = Bottom + (Top-Bottom)/
(1+10^((LogIC50-X)*HillSlope)) where X is the logarithm of concentration).
Abbreviations: MP, α-methylprednisolone; CDP-MP, polymer conjugate; IC50, half-maximal (50%) inhibitory concentration; Con A, Concanavilin A; PHA, phytohemagglutin.International Journal of Nanomedicine 2008:3(3) 366
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The second parameter evaluated was dorsoplantar 
swelling, a quantitative measurement of arthritic symptoms 
(Figure 4). In the mouse model of collagen-induced arthritis 
disease progression results in a temporal rise and subsequent 
decrease of this parameter. Daily doses of all free MP at 0.01, 
0.1, and 1.0 mg/kg/day showed similar results to weekly 
doses of CDP-MP at 0.07 mg/kg/week with no signiﬁ  cant 
reductions in dorsoplantar swelling compared to untreated 
animals (p  0.33). However, after day 28, the two highest 
doses of CDP-MP at 0.7 and 7.0 mg/kg/week signiﬁ  cantly 
reduced dorsoplantar swelling (p  0.03).
Histological evaluation was performed to determine the 
extent of joint damage at day 42. An overall score based on 
collective points from synovitis, pannus formation (thickened 
layers of granulation tissue) and architectural changes was 
assessed. Histological evidence of reduced collective points 
consistent with the dorsaplantar swelling data was observed 
(Figures 5 and 6). Vehicle treated control mice showed 
arthritis with diffuse synovitis and bone destruction. CDP 
treated mice showed scattered synovitis and bone resorption. 
Free MP-treated mice at 0.01 and 0.1 mg/kg/day showed 
minimal inhibition of inﬂ  ammation. Mice treated with free 
MP at 0.01 mg/kg/day showed moderate synovitis and full 
thickness bone defect whereas mice treated at 0.1 mg/kg/day 
showed diffuse synovitis and bone resorption. CDP-MP 
at 0.7 mg/kg/week resulted in sparse synovitis with only 
small area of bone resorption. Mice treated with CDP-MP 
at 7.0 mg/kg/week showed scattered synovitis with small 
area of bone resorption. CDP-MP at 7.0 mg/kg resulted in a 
signiﬁ  cant reduction in synovitis, pannus, and bone destruc-
tion compared to control animals (p  0.04). Free MP at all 
dose levels and CDP-MP at 0.07 and 0.7 mg/kg did not show 
signiﬁ  cant reduction in histological scores.
Discussion
The investigation of a CDP based nanoparticle prodrug con-
taining MP for the treatment of RA was based on the following 
main considerations: First, corticosteroids are effective in the 
management of RA when administered systemically (orally 
or through i.m. or i.v. injection) or locally through direct 
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Figure 3 Arthritis score by a standardized method (ranges 0 to 4). After combining scores for all paws, the maximum possible score is 16. Mean arthritis score (n = 5) is 
shown except for low doses of MP alone (0.01 and 0.1 mg/kg/day). Arthritis scores for these groups were similar to control animals (data not shown). Standard error of the 
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intra-articular injections (Armstrong et al 1981; Neumann 
et al 1985). However, the rapid clearance and unfavorable 
biodistribution of MP requires frequent and high doses to 
achieve the desired therapeutic effect. This in turn can lead 
to a number of side effects, making it desirable to develop 
a parenteral formulation that would allow for lower doses, 
less systemic exposure and a reduction in dosing frequency. 
Second, nanoparticle formulations have been shown to exhibit 
inﬂ  ammatory site targeting in various autoinﬂ  ammatory dis-
eases, including RA (Boerman et al 1997; Dams et al 2000). 
Third, CDP based prodrugs of poorly water soluble drugs self-
assemble into stabilized nanoparticles with a size of 30–50 nm 
(Cheng et al 2003; Schluep et al 2006a, 2006b).
The purpose of the current study was to investigate if 
a conjugate of CDP with MP could improve the efﬁ  cacy 
and reduce the dosing frequency compared to the small 
molecule drug in an animal model of RA. To that end we 
prepared a CDP-MP conjugate by covalently attaching a 
glycinate derivative of MP to a high molecular weight CDP 
(117 kD) through an ester linkage. The resulting polymer 
conjugate was highly water soluble (200 mg/mL) and 
self-assembled into nanoparticles with an average diameter 
of 27 nm. This is consistent with our previous observations 
with this cyclodextrin-based polymer system. For example, 
a glycinate ester conjugate of camptothecin with the same 
parent polymer (IT-101) resulted in nanoparticles in a similar 
size range. This self-assembly requires covalent attachment 
of the small molecule drug to the polymer. Parent polymer 
by itself and conjugate from which all the drug was released 
showed a particle size of 9.7 nm by DLS, consistent with the 
expected hydrodynamic diameter of single strand polymer.
Release kinetics
Release kinetics of MP from CDP-MP were studied in vitro 
in PBS and human plasma. The half-life in PBS and plasma 
was 50 h and 19 h, respectively. Glycinate ester prodrugs 
can be activated by base catalyzed hydrolysis as well as 
enzymatically by esterases. The increased release in plasma 
is consistent with esterase catalyzed cleavage of the glyci-
nate ester. However, the half-life of the CDP-MP prodrug 
Figure 4 Change in dorsoplantar swelling. CDP-MP at 0.7 and 7 mg/kg show signiﬁ  cant reduction in dorsoplantar swelling. Mean dorsoplantar swelling (n = 5) is shown except 
for low doses of MP alone (0.01 and 0.1 mg/kg/day). Dorsoplantar swelling for these groups was similar to control animals (data not shown). SEM of dorsoplantar swelling is 
shown only for control vs. treatments that were signiﬁ  cantly effective (p  0.05).
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in plasma is still considerably longer than what is typically 
observed with small molecule ester prodrugs, which nor-
mally have half lives of 1 to 3 hours (Mørk and Bundgaard 
1992; Sriram et al 2004). This resistance to esterase cleav-
age is most likely due to steric hindrance by the polymer or 
inaccessibility of the ester groups within the nanoparticle. 
Appropriate linker stability in plasma allows for a long 
circulating pool of prodrug with extended release kinet-
ics, reducing the need for frequent dosing. While we have 
not studied the pharmacokinetics of the present compound 
in vivo, based on our previous investigations of similar CDP 
conjugates, one can expect substantial improvements in the 
Figure 5 Histology photomicrographs of Hematoxylin and Eosin stained joints of mice with collagen induced arthritis. A. Vehicle control with diffuse synovitis and bone 
destruction. B. CDP with scattered synovitis and bone resorption. C. Free MP (0.01 mg/kg/day) with moderate synovitis and full thickness bone defect. D. Free MP 
(0.1 mg/kg/day) with diffuse synovitis and bone resorption. E. CDP-MP (0.7 mg/kg/week) with sparse synovitis and small area of bone resorption F. CDP-MP (7 mg/kg/week) 
with scattered synovitis and small area of bone resorption.International Journal of Nanomedicine 2008:3(3) 369
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pharmacokinetics of the nanoparticle compared to the small 
molecule analog (Schluep et al 2006b). With camptothecin as 
a model compound, the plasma half-life of the small molecule 
in rats was less than 2 hours whereas the CDP conjugate 
showed a plasma half-life of close to 20 hours.
Efﬁ  cacy in vitro
The polymeric conjugates are expected to be inactive in their 
prodrug form and must release the drug from the delivery 
system to provide their anti-inﬂ  ammatory effect. We there-
fore studied the ability of MP and CDP-MP to inhibit the 
proliferation of human lymphocytes in a 3- and 5-day assay 
in vitro. In order to compare the ability to inhibit proliferation 
between free MP and CDP-MP, the cultures were exposed 
to different concentrations of the drugs in the presence of 
phytohemagglutinin (PHA) or concanavilin A (Con A) as 
mitogens. Stimulation of isolated human lymphocytes with 
Con A and PHA, two lectin mitogens, resulted in proliferation 
of the control cells. MP acts at the G1 phase by inhibiting 
cytokine gene transcription in antigen presenting cells (eg, 
IL-1) and T lymphocytes (eg, IL-2). The Con A stimulated 
cells were more sensitive to treatment with both MP or 
CDP-MP compared to the PHA stimulated cells. The reason 
for this difference is unknown at this time, however, the gen-
eral response to treatment was with MP and CDP-MP was 
similar in both cases. At an early timepoint (3 days) CDP-MP 
was less potent than free MP by a factor of 4 in the case of 
Con A and by a factor of 23 in the case of PHA as stimulus. 
While the potency of MP remained about the same in the 5 
day assay, the potency of CDP-MP was increased consider-
ably. In fact, CDP-MP was about 36-fold more potent than 
free MP at day 5 in the Con A stimulated cells and only 
about 4-fold less potent than free MP in the PHA stimulated 
cells. This delayed effect is consistent with a slow release of 
the drug over time. These data also show that release of the 
drug from the polymer conjugate is necessary for a biologic 
effect to occur.
Rationale of methylprednisolone dosage
Studies in rat and murine CIA models indicate that daily 
doses of 1–4 mg/kg prednisolone or methylprednisolone 
orally, or by subcutaneous or intraperitoneal administration 
Figure 6 Histological scores of synovitis, pannus and architecture. CDP-MP at 7 mg/kg/week shows signiﬁ  cant improvement in all parameters such as synovitis, pannus and 
architecture compared to untreated controls (p  0.04). Mean ± SEM (n = 5) is shown.
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were effective in reducing paw edema, arthritis score, joint 
destruction and pro-inﬂ  ammatory cytokine levels (Geiger 
1994; Smith and Sly 1996; Kamada et al 1997; Paul-Clark 
et al 2002; Rioja 2004; Mancini 2007). The low end of this 
range was chosen as the maximum daily dose for free MP 
whereas CDP-MP was dosed at equivalent doses but on a 
weekly schedule. Because daily intravenous injections in 
mice are difﬁ  cult to execute for prolonged periods of time due 
to tail vein scarring, the more reproducible and convenient 
subcutaneous route was chosen for the MP control animals. 
This is supported by studies in rats indicating that subcutane-
ous and intravenous injections of MP are expected to result 
in equivalent pharmacodynamics and activity (Frenkel and 
Havenhill 1963; Hazra 2007).
Efﬁ  cacy in vivo
The efﬁ  cacy of CDP-MP was studied in vivo in a collagen 
induced arthritis model. In this model, arthritis is induced in 
mice by subcutaneous injection of bovine collagen type II. 
Animals develop the typical signs of arthritis such as joint 
swelling and histological changes such as cellular inﬁ  ltrates, 
synovial hypertrophy and bone destruction. Many of these 
changes happen in a distinct temporal manner, therefore 
treated and untreated animals are monitored over a period of 
42 days. All treatments were well tolerated with no signiﬁ  -
cant body weight changes observed in any of the treatment 
groups. Joint swelling was scored by arthritis score which is 
a standardized method to measure swelling and hyperemia. 
At earlier time points, both free MP and CDP-MP did not 
show signiﬁ  cant difference in the reduction of inﬂ  ammation. 
However, after 28 days, signiﬁ  cant decreases in arthritis score 
were shown in animals treated with weekly doses of CDP-MP 
at 0.7 and 7.0 mg/kg by intravenous injection. Free MP at the 
highest dose (1.0 mg/kg daily, 7.0 mg/kg weekly) resulted 
in a reduction in arthritis score that was similar to the one 
observed with 0.07 mg/kg CDP-MP, however these effects 
were not statistically signiﬁ  cant compared to control animals. 
A second parameter analyzed was dorsoplantar swelling, 
a quantitative measurement of arthritic symptoms. Dorso-
plantar swelling was reduced to baseline in animals treated 
weekly with 0.7 and 7.0 mg/kg of CDP-MP. In contrast free 
MP given daily at equivalent cumulative doses had a non-
signiﬁ  cant effect on dorsoplantar swelling. This result was 
conﬁ  rmed by histological evaluation of the inﬂ  amed joints, 
where only the high dose group of, CDP-MP at 7.0 mg/kg 
showed a signiﬁ  cant reduction in bone resorption, pannus 
formation, and synovitis. In summary, weekly CDP-MP 
was effective in reducing the symptoms of collagen induced 
arthritis in mice at doses up to 100-fold lower using weekly 
rather than daily injections compared with MP alone.
In vitro studies presented here and in vivo pharmaco-
kinetics and biodistribution studies with a similar polymer 
nanoparticle prodrug (Schluep et al 2006b) show that this may 
be achieved through three speciﬁ  c mechanisms: (A) Increased 
circulation half-life and slow release of drug from the nanopar-
ticle prodrug. We have seen plasma half-lives of close to 
20 hours in rats dosed with a similar nanoparticle containing 
camptothecin. Combined with the slow release kinetics of 
MP in plasma shown in this study, this allows for a reduction 
in dosing frequency compared to the small molecule analog 
MP with a reported plasma half-life of less than two hours. 
(B) Increase in biodistribution to target organs. We and others 
have shown that long circulating nanoparticles accumulate in 
organs of the reticuloendothelial system such as spleen and 
liver (Storm 1995; Gaur et al 2000; Zhang and Mehvar 2001a, 
2001b; Brigger et al 2002; Schluep et al 2006b). Additionally, 
multiple publications have shown that nanoparticles accumu-
late in sites of inﬂ  ammation, such as arthritic joints (Boerman 
1997; Dams 2000; Metselaar et al 2003). (C) Multiple reports 
show increased enzymatic activity including esterase activity 
at sites of inﬂ  ammation (Mørk and Bundgaard 1992; Sriram 
2004). This provides a site speciﬁ  c release mechanism of the 
MP from its polymer carrier.
In an attempt to reduce the toxicity and increase the effec-
tiveness of immunosuppressants, local immunosuppression 
at the site of inﬂ  ammation has been used for the treatment of 
arthritis (Bliddal 2006; Bouysset 2006; Neustadt 2006). This 
strategy is based on evidence indicating that in addition to the 
inhibition of the systemic immune system (such as inhibition 
of splenic lymphocytes), the inhibition of immune events at 
the site of inﬂ  ammation provides increased patient beneﬁ  t. 
Here we present data that CDP conjugates of MP showed 
improved efﬁ  cacy when compared to free MP in a collagen 
induced arthritis model. CDP conjugation may be an attrac-
tive strategy for targeting MP and other immunosuppressive 
agents to their sites of action.
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